Analysts Anticipate Athersys, Inc. (ATHX) to Announce ($0.08) Earnings Per Share

Shares of Athersys, Inc. (NASDAQ:ATHX) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus target price of $6.00 for the company and are expecting that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also given Athersys an industry rank of 80 out of 255 based on the ratings given to its competitors.

ATHX has been the topic of several recent analyst reports. BidaskClub lowered Athersys from a “buy” rating to a “hold” rating in a report on Friday, June 22nd. Zacks Investment Research lowered Athersys from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Finally, Maxim Group reissued a “buy” rating and issued a $6.00 target price on shares of Athersys in a report on Tuesday, July 31st.

In other Athersys news, insider Laura K. Campbell sold 28,868 shares of the company’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $2.01, for a total value of $58,024.68. Following the completion of the transaction, the insider now owns 590,424 shares in the company, valued at $1,186,752.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Lehmann, Jr. sold 15,000 shares of the company’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $1.88, for a total transaction of $28,200.00. Following the completion of the transaction, the insider now owns 517,373 shares of the company’s stock, valued at approximately $972,661.24. The disclosure for this sale can be found here. Insiders sold 76,088 shares of company stock worth $149,487 in the last three months. 18.60% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its stake in shares of Athersys by 214.9% during the first quarter. JPMorgan Chase & Co. now owns 69,370 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 47,339 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Athersys by 21.3% during the second quarter. Renaissance Technologies LLC now owns 439,900 shares of the biopharmaceutical company’s stock worth $867,000 after buying an additional 77,100 shares during the period. Northern Trust Corp boosted its stake in shares of Athersys by 7.1% during the first quarter. Northern Trust Corp now owns 1,215,690 shares of the biopharmaceutical company’s stock worth $2,225,000 after buying an additional 80,708 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in shares of Athersys by 50.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 250,900 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 84,600 shares during the period. Finally, Alps Advisors Inc. acquired a new stake in shares of Athersys during the second quarter worth about $394,000. Institutional investors own 19.02% of the company’s stock.

Shares of Athersys stock traded down $0.01 during trading hours on Monday, reaching $1.99. 520,140 shares of the company were exchanged, compared to its average volume of 698,385. Athersys has a 1 year low of $1.29 and a 1 year high of $3.09. The firm has a market capitalization of $291.03 million, a P/E ratio of -6.86 and a beta of -0.61.

Athersys (NASDAQ:ATHX) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported $0.05 earnings per share for the quarter. Athersys had a negative return on equity of 61.52% and a negative net margin of 106.99%. The business had revenue of $19.39 million for the quarter, compared to analyst estimates of $12.82 million. On average, equities research analysts expect that Athersys will post -0.21 EPS for the current year.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Featured Story: How is inflation measured?

Get a free copy of the Zacks research report on Athersys (ATHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply